LQDA
MaterialsLiquidia Corp
Live · NASDAQ · May 9, Close
What's Moving LQDA Today?
No stock-specific AI insight has been generated for LQDA yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
LQDA News
22 articles- Liquidia CEO Roger Jeffs sells $3.07m in company stock By Investing.comInvesting.com Australia·May 8, 2026
- Affiliate plans sales for LQDA (NASDAQ: LQDA) — multiple 10b5-1 trades listedStock Titan·May 8, 2026
- Alector (ALEC) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 7, 2026
- Viatris Q1 EPS Beats Estimates, Revenues up 8% Driven by Greater ChinaYahoo Finance·May 7, 2026
- ADMA Q1 EPS Jumps 73% Y/Y, Revenues Slip, 2026 View DownYahoo Finance·May 7, 2026
- Liquidia Corporation to Participate in Upcoming Investor ConferencesYahoo Finance·May 6, 2026
- Liquidia Corporation to Report First Quarter 2026 Financial Results on May 11, 2026Yahoo Finance·May 4, 2026
- Does Tom Steyer’s YUTREPIA Endorsement Reframe the Bull Case for Liquidia (LQDA)?Yahoo Finance·May 4, 2026
- Liquidia Corporation (LQDA): Billionaire Tom Steyer Admires This Pharma StockYahoo Finance·May 2, 2026
- This Drug Stock Nears A Buy Point, With Profit Set To ExplodeYahoo Finance·Apr 27, 2026
- Liquidia Corp (LQDA) Surged Following the Successful Acceptance of Its YUTREPIA DrugYahoo Finance·Apr 24, 2026
- Liquidia's (LQDA) CEO Sells 53,000 Shares for $2.1 MillionMotley Fool·Apr 19, 2026
- Is It Too Late To Consider Liquidia (LQDA) After Its Recent Share Price Surge?Yahoo Finance·Apr 13, 2026
- Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsightGlobeNewswire Inc.·Apr 8, 2026
- Liquidia's Chairman Sold Company Shares Worth $2.5 Million. Should Investors Avoid the Stock?The Motley Fool·Apr 5, 2026
- Does Liquidia Corporation (LQDA) Have the Potential to Rally 34.47% as Wall Street Analysts Expect?Yahoo Finance·Apr 3, 2026
- Should Insider Stock Sale and Analyst Optimism Around Pulmonary Drugs Require Action From Liquidia (LQDA) Investors?Yahoo Finance·Apr 1, 2026
- AZN Posts Data From Hypophosphatasia Program on Efzimfotase AlfaYahoo Finance·Apr 1, 2026
- Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host DiseaseYahoo Finance·Mar 31, 2026
- Wells Fargo Lifts PT on Liquidia Corporation (LQDA) to $51 From $44 – Here’s WhyYahoo Finance·Mar 31, 2026
- The Chief Commercial Officer of Liquidia (LQDA) Sold 80,000 Shares for $2.8MThe Motley Fool·Mar 28, 2026
- Novartis Bolsters Immunology Pipeline With Excellergy DealYahoo Finance·Mar 27, 2026
All 22 articles loaded
Price Data
Fundamentals
Trading
About Liquidia Corp
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.